在被送往急诊室的肥胖患者中,处方激发药物的做法
Journal of psychiatric practice
|September 7, 2023
概括
这项研究发现,肥胖患者和非肥胖患者之间的激发药物剂量没有显著差异. 需要进一步的研究来证实在激动人群中服用抗精神病药物和二二类药物的体重考虑方面的发现.
科学领域:
- 紧急医疗 紧急医疗
- 临床药理学 临床药理学
背景情况:
- 体重显著影响药物剂量,但其在治疗肥胖患者使用抗精神病药物和二zepine治疗兴奋的作用仍然未被评估.
- 临床研究尚未专门评估肥胖人口中激发药物的基于体重的剂量.
研究的目的:
- 为了确定体重是否会影响激动患者的抗精神病药物和二二胺剂量.
- 分析肥胖与非肥胖个体中激发药物的处方模式.
主要方法:
- 一项回顾性队列研究比较了肥胖和非肥胖的成年患者,这些患者在急诊室接受肠道抗精神病药物或二氨酸以激发焦虑.
- 主要结局包括24小时的药物总剂量 (罗马зин和洛拉泽帕姆等价物);次要结局评估了初始剂量,重复剂量和时间.
主要成果:
- 该研究包括每个队列的115名患者遭遇,具有类似的基线特征.
- 肥胖和非肥胖组的24小时抗精神病药物和二二类药物的平均剂量相似 (分别P=0.157和P=0.750).
- 在队列之间的二次结果中没有观察到统计学上显著的差异.
结论:
- 这项研究没有证明,与非肥胖患者相比,肥胖患者需要更高的激发药物剂量.
- 专注于特定药物,刺激原因或病态肥胖的前性试验是有必要的,以证实这些发现,并探索基于体重的潜在剂量差异.
相关概念视频
SBAR II: Application of SBAR
4.5K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.5K
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Antidepressant Drugs: MAOIs and Other Agents
270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
378
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
378
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
297
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
297


